CytoDyn is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn’s lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments.
1111 Main Street
Vancouver, WA 98660 US
Pharmaceutical Preparation Manufacturing (325412)
Pharmaceutical Preparations (2834)